Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients

NCT04573153 is registered in ClinicalTrials.gov with ScandiBio Therapeutics AB as lead sponsor.

NCT NCT04573153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04573153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
Lead sponsor
ScandiBio Therapeutics AB
Phase
Phase 2/3
Overall status
Terminated
Start date
September 21, 2020
Completion date
May 5, 2022
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19